Professor Anna Nowak

PROFESSOR ANNA NOWAK

DIRECTOR, NCARD

Anna completed her medical training at UWA in 1990, medical oncology training (FRACP) in 2000, and a PhD at UWA in 2003 in tumour immunology. With her laboratory-based PhD thesis, followed by a postdoctoral fellowship in clinical trials and quality of life research, Anna has gained a unique translational perspective with expertise in laboratory science, clinical trials, patient-rated outcomes and quality of life. She has longstanding research and clinical interests in malignant mesothelioma.  As the Director of NCARD Professor Nowak leads and collaborates with around 35 scientific staff and graduate students. Anna is passionate about patient-doctor communication, mentoring, and women in oncology and science.

CURRENT PROJECTS

RECENT HIGHLIGHTS

  • Appointed Associate Dean (Research) and Deputy Executive Dean of the Faculty of Medical and Health Sciences at UWA.
  • Invited to Board of Cancer Council of Western Australia 2020.

RECENT PUBLICATIONS

  • Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Zemek RM, De Jong E, Chin WL, Schuster IA, Fear VS, Casey TS, Forbes C, Dart SJ, Leslie C, Zaitouny A, Small M, Boon L, Forrest ARR, Muiri DO, Degli-Espositi MA, Millward MJ, Nowak AK, Lassmann T, Bosco A, Lake RA, Lesterhuis WJ. Science Translational Medicine; 11(501) pii: eaav7816, 2019.
  • Concurrent and Adjuvant Temozolomide for 1p/19q non-co-deleted anaplastic glioma: interim results of the intergroup CATNON trial (EORTC study 26053-22054). van den Bent MJ, Baumert BG, Erridge SC, Vogelbaum MA, Nowak AK, Wick W, Sanson M, Brandes AA, Clement PM, Baurain J-F, Mason WP, Wheeler H, Chinot OL, Weller M, Golfinopoulos V, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Gorlia R, Kros JM. The Lancet. 390(10103): 1645-53, 2017.
  • Tremelimumab as second- and third-line treatment in relapsed malignant mesothelioma (MM): a phase 2b, randomised, double blind, placebo-controlled study (DETERMINE). Maio M, Scherpereel A, Calabro L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman P, Kindler HL. Lancet Oncology 18(9): 1261-73, 2017.
  • The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T descriptors in the forthcoming Eighth edition of the TNM classification for pleural mesothelioma. Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Bille A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW, on behalf of the Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. Journal of Thoracic Oncology 11(12); 2089-99, 2016.
  • Cook AM, McDonnell AM, Millward M, Lake RA, Nowak AK. Co-medication with dexamethasone of mesothelioma patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology, 5(3) 11p, 2016.

MORE INFORMATION

Menu